Gastrointestinal Cancer News

ASCO has named molecular profiling driving progress in gastrointestinal cancer as its Advance of the Year, acknowledging improvements in treatment that have resulted from molecular testing of patients’ tumors.

The FDA lifted its clinical hold on a study evaluating BPX-601 and rimiducid for patients with previously treated metastatic pancreatic or prostate cancers, according to a press release from the agent’s manufacturer.

The organization Fight Colorectal Cancer is celebrating that the Removing Barriers to Colorectal Cancer Screening Act has been recently signed into law.

Roswell Park Comprehensive Cancer Center has promoted four physicians to leadership roles in its clinical research program.

Terence M. Williams, MD, PhD, has been appointed chair of City of Hope’s department of radiation oncology.

Tislelizumab extended OS compared with chemotherapy for patients with previously treated advanced esophageal squamous cell carcinoma, according to topline data released by the agent’s manufacturer.

A coalition of 76 cancer organizations today released an open letter urging Americans to make cancer care a priority amid the COVID-19 pandemic.

Although colorectal cancer is most commonly diagnosed among those aged older than 50 years, we have seen a decrease in cases diagnosed in that age group due to screening and prevention. Unfortunately, the rates of colorectal cancer among those aged younger than 50 years have been rising in the United States, with an estimated 12% of cases, or about 18,000, diagnosed among this younger population in 2020. Recently, the American Cancer Society and the USPSTF lowered the recommended age to begin screening to 45 years.

Black individuals have the highest incidence and mortality rates of colorectal cancer of any racial or ethnic group in the United States.

Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated advanced cholangiocarcinoma, according to final results of the phase 3 ClarIDHy trial presented at Gastrointestinal Cancers Symposium.